Teledyne Technologies agreed Monday to acquire medical imaging components maker Varex Imaging Corporation for $18.90 per share in an all-cash transaction valued at approximately $1.1 billion, marking the largest single addition to Teledyne's digital imaging segment since its $8 billion FLIR Systems acquisition in 2021.

The deal, announced jointly by the companies on August 10, represents an 88 percent premium over Varex's closing stock price on Friday and immediately sent Varex shares soaring 48 percent in Monday trading. For Teledyne, the acquisition fills critical technology gaps in high-radiation X-ray applications while consolidating a fragmented supply chain for next-generation computed tomography detectors.

The transaction is expected to close in the first quarter of 2027, subject to customary regulatory approvals and shareholder votes. Varex stockholders will receive $18.90 in cash for each share they own, with no stock component to the consideration.

The Strategic Logic Behind the Deal

Teledyne Technologies, headquartered in Thousand Oaks, California, has built a diversified portfolio of imaging and sensing technologies across aerospace, defense, industrial, and medical applications. The company's Digital Imaging segment includes well-known brands such as Teledyne FLIR, Teledyne e2v, and Teledyne DALSA, covering visible, infrared, ultraviolet, and X-ray imaging capabilities.

Varex Imaging, based in Salt Lake City, specializes in designing and manufacturing critical components for X-ray imaging systems, including X-ray tubes, digital detectors, and image processing solutions used in medical diagnostics, cancer therapy, industrial inspection, and security screening applications.

The complementary nature of the two companies' product lines drove the acquisition logic, according to Teledyne's CEO Robert Mehrabian. Teledyne currently manufactures X-ray detectors but does not offer detector products designed for certain high-radiation applications, particularly in oncology radiation therapy systems where Varex holds significant market share and specialized technical expertise.

"Varex brings technologies that largely complement our existing imaging business rather than creating significant overlap," Mehrabian said during Monday's announcement call. "Their strength in medical radiation therapy detectors and high-energy industrial inspection fills gaps in our current portfolio while expanding our addressable market in medical imaging."

The Medical Imaging Growth Opportunity

The medical imaging market has experienced robust growth over the past five years, driven by aging populations in developed economies, increasing cancer screening and treatment demand, and technological advances that have expanded the clinical applications for X-ray based diagnostics.

Varex's products are critical components in computed tomography scanners, digital radiography systems, fluoroscopy equipment, and radiation therapy machines manufactured by major medical equipment companies including Siemens Healthineers, GE HealthCare, Philips, and Canon Medical. The company's X-ray tubes and detectors represent enabling technologies that these OEM customers cannot easily design in-house or source from alternative suppliers.

The radiation therapy segment, where Varex holds particularly strong market positions, has shown especially strong growth as cancer treatment protocols increasingly rely on precise imaging guidance for radiation dose delivery. Intensity-modulated radiation therapy and image-guided radiation therapy systems depend on high-performance X-ray detectors that can operate reliably in the extreme radiation environments adjacent to linear accelerators.

Financial Profile and Revenue Synergies

Varex reported annual revenue of approximately $850 million for its most recent fiscal year, with operating margins in the mid-teens range. The company's business model includes both product sales of X-ray tubes and detectors as well as recurring aftermarket revenue from replacement tubes, detector upgrades, and service contracts.

Teledyne expects the acquisition to be accretive to earnings within the first full year following close, driven by a combination of modest cost synergies and revenue growth opportunities. The company highlighted cross-selling potential where Teledyne's existing relationships with aerospace and defense customers could open new markets for Varex's industrial inspection technologies.

The $1.1 billion purchase price includes both Varex's equity value and the assumption of existing debt and equity compensation awards outstanding as of April 3, 2026. Teledyne plans to finance the transaction through a combination of existing cash, available credit facilities, and potentially new debt issuance depending on market conditions at closing.

Industry Consolidation Continues

The Teledyne-Varex deal represents the latest in a wave of consolidation within the imaging components and sensor systems industries. The fragmented nature of specialized imaging technology suppliers has created acquisition opportunities for larger platforms seeking to build comprehensive portfolios across multiple imaging modalities and end markets.

Teledyne's strategy over the past decade has focused on acquiring specialized imaging and sensing businesses, integrating them into its operational infrastructure, and leveraging common technology platforms and customer relationships across multiple end markets. The FLIR acquisition in 2021 brought thermal imaging expertise that Teledyne has subsequently integrated with its visible imaging and analytics capabilities.

Varex will operate within Teledyne's Digital Imaging segment following the close, maintaining its Salt Lake City headquarters and manufacturing operations while gaining access to Teledyne's broader technology resources and capital structure.

What It Means for Medical Equipment Makers

The acquisition creates a larger, more comprehensive supplier of imaging components for medical equipment manufacturers. For Varex's OEM customers, the transaction could provide benefits in the form of accelerated technology development through Teledyne's larger R&D investment capability and potentially more stable long-term supply relationships backed by Teledyne's stronger balance sheet.

However, consolidation among critical component suppliers also raises potential concerns about supply chain concentration and pricing leverage. Medical equipment manufacturers typically prefer to maintain multiple suppliers for critical components or to develop internal capabilities for strategic technologies. The combination of Teledyne and Varex will create a dominant position in certain X-ray component categories, potentially limiting alternatives for OEM customers.

Industry analysts who cover the medical equipment sector noted that Teledyne's acquisition of Varex follows a familiar playbook in specialized component markets: consolidate fragmented suppliers, invest in next-generation technology development, and gradually shift the value capture within the supply chain toward the component supplier with differentiated technology.

For Varex shareholders, the $18.90 per share offer represents a substantial premium and liquidity event after years of stock price volatility and modest growth. Varex shares had traded as high as $32 in 2022 but had declined to the $10 range by early 2026 as medical equipment demand normalized following the pandemic-driven surge.

The transaction is expected to receive antitrust approval without significant conditions, given limited direct overlap between Teledyne's and Varex's product lines in most categories. Shareholder votes at both companies are expected to occur in the fourth quarter of 2026, with regulatory review processes running in parallel.